NCT05917431View on ClinicalTrials.gov

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Unresectable Hepatocellular CarcinomaOligometastatic Disease
Interventions
COMBINATION_PRODUCT

SBRT plus tislelizumab and regorafenib

Participants will receive SBRT plus tislelizumab and regorafenib concurrently

Trial Locations (1)

100041

RECRUITING

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER